Research Library
Tap to Pause Rotation
39-amino-acid triple GLP-1/GIP/glucagon agonist (Aib at 2 & 13)
Metabolic / Weight Management

Retatrutide

A triple-receptor agonist (GLP-1, GIP, glucagon) — one of the most potent metabolic peptides in current research.

Mechanism of Action

Compound targeting metabolic efficiency and cellular energy production.

Evidence Chain

Retatrutide

COMPOUND

1 Research Goal

• Weight Management

Evidence Strength

Clinical Trial

24 articles sourced

Knowledge Graph

(25 connections)
CompoundGoalArticleArticleArticle
Compound (Center)
Research Goal
Linked Article

Research Evidence

(24)

Ligandrol (LGD-4033): Evidence-Based Research Review

5 min

Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimi

Clinical Trial

Enobosarm (Ostarine / MK-2866): Evidence-Based Research Review

5 min

**Class:** SARM (Selective Androgen Receptor Modulator)

Clinical Trial

Clomiphene Citrate: Evidence-Based Research Review

6 min

Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative classified as a Selective Estrogen Receptor Modulator (SERM). Originally developed for the induction of ovulation in women with anovulatory infertility, it has become a cornerstone of reproductive medicine. CC operates as a race

Clinical Trial

Tamoxifen Citrate: Evidence-Based Research Review

6 min

Tamoxifen citrate is a non-steroidal triphenylethylene derivative and the prototypic Selective Estrogen Receptor Modulator (SERM). Originally developed as a contraceptive, it has become a cornerstone in the treatment and prophylaxis of estrogen receptor-positive (ER+) breast cancer. Tamoxifen exhibi

Clinical Trial

Oxandrolone: Evidence-Based Research Review

6 min

Oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) is a synthetic oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a unique substitution of an oxygen atom for the carbon at the C-2 position in the A-ring, oxandrolone exhibits a high anabolic-

Clinical Trial

Nandrolone Decanoate: Evidence-Based Research Review

6 min

Nandrolone decanoate (ND) is a long-acting injectable ester of the anabolic-androgenic steroid (AAS) nandrolone (19-nortestosterone). Characterized by a high anabolic-to-androgenic ratio, ND has been utilized clinically for decades to treat conditions involving protein catabolism, bone density loss,

Clinical Trial

Testosterone Enanthate: Evidence-Based Research Review

6 min

Testosterone enanthate (TE) is a long-acting esterified formulation of the primary endogenous androgen, testosterone. Since its clinical introduction in the 1950s, it has served as a cornerstone for testosterone replacement therapy (TRT) in male hypogonadism and a reference compound in clinical rese

Clinical Trial

Toremifene Citrate: Evidence-Based Research Review

5 min

Toremifene citrate is a chlorinated triphenylethylene derivative and a second-generation selective estrogen receptor modulator (SERM). Structurally analogous to tamoxifen, toremifene was developed to maintain the therapeutic efficacy of ER-antagonism in breast tissue while potentially improving the

Clinical Trial

Raloxifene: Evidence-Based Research Review

6 min

Raloxifene is a second-generation selective estrogen receptor modulator (SERM) of the benzothiophene class. Developed to address the limitations of first-generation SERMs like tamoxifen, raloxifene exhibits distinct tissue-specific effects: it acts as an estrogen receptor (ER) agonist in bone and li

Clinical Trial

Methenolone Enanthate: Evidence-Based Research Review

6 min

Methenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a 1-methyl modification and a 2-oxo group, it exhibits a high anabolic-to-androgenic ratio and is notable for its inability to aromatize into estrogen. Origina

Clinical Trial

Stanozolol: Evidence-Based Research Review

5 min

Stanozolol is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a high anabolic-to-androgenic ratio, it is clinically distinguished by its pyrazole ring modification and 17α-alkylation. Originally developed for the treatment of hereditary angioede

Clinical Trial

Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist — Clinical Evidence in Obesity and MASH

6 min

Survodutide is a dual GLP-1 and glucagon receptor agonist in clinical development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This review summarizes the clinical evidence.

Clinical Trial

CagriSema (Cagrilintide + Semaglutide) Combination Therapy: Clinical Evidence from the REDEFINE Trial Program

6 min

CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 receptor agonist) for the treatment of obesity. The REDEFINE clinical development program evaluates the additive weight-loss effects of co-administering amylin and incretin pathway agonism.

Clinical Trial

GLP-1 Receptor Agonism in Metabolic Signaling

8 min

Survey of GLP-1, GIP, and glucagon receptor research for metabolic signaling and incretin physiology.

Clinical Trial

Telomerase Activation and Cellular Senescence Pathways

9 min

Survey of telomerase and mitochondrial peptide research in aging and senescence pathways.

Clinical Trial

YK-11: Evidence-Based Research Review

5 min

YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal

Peer-Reviewed

Testolone (RAD-140): Evidence-Based Research Review

5 min

Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.

Preclinical

Cardarine (GW-501516): Evidence-Based Research Review

6 min

Cardarine (GW-501516) is a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist originally developed through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline (GSK) for the treatment of metabolic and cardiovascular diseases. Although frequently categorized as a

Preclinical

Andarine (S-4): Evidence-Based Research Review

5 min

Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the

Preclinical

Drostanolone Propionate: Evidence-Based Research Review

6 min

Drostanolone propionate (2α-methyl-5α-androstan-17β-ol-3-one propionate) is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Originally developed for the treatment of advanced breast cancer in postmenopausal women, it is characterized by its inability to aromatiz

Preclinical

Boldenone Undecylenate: Evidence-Based Research Review

6 min

Boldenone undecylenate, a synthetic derivative of testosterone originally developed for veterinary use, is a long-acting injectable anabolic-androgenic steroid (AAS). Characterized by a double bond between the C1 and C2 positions, the compound exhibits a favorable ratio of anabolic to androgenic act

Preclinical

Trenbolone Acetate: Evidence-Based Research Review

6 min

Trenbolone acetate (TBA) is a potent synthetic 19-nortestosterone derivative classified as an anabolic-androgenic steroid (AAS). Originally developed for veterinary applications—specifically to increase muscle mass and feed efficiency in beef cattle—TBA has become a focal point of pharmacological in

Preclinical

Adalank and the Selank Peptide Class: Anxiolytic Peptide Pharmacology and Translational Rationale

6 min

Adalank is a synthetic analog of the anxiolytic peptide Selank incorporating an adamantane moiety. This review outlines the pharmacological rationale and preclinical evidence from the Selank peptide class that informs its development.

Preclinical

Peptide Synergy: Metabolic System Stacking

7 min

A systematic review of metabolic peptide synergy, examining how dual and triple receptor agonists interact within the incretin pathway.

Review

Overview

Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it represents the next frontier in metabolic peptide therapeutics, moving beyond dual agonism to harness the complementary effects of three key metabolic hormones. Retatrutide is currently in Phase 3 clinical trials and has generated significant interest for its potential to achieve weight loss results exceeding even tirzepatide.

Mechanism of Action

Retatrutide's triple agonism produces effects beyond those of dual GIP/GLP-1 agonists. GLP-1 receptor activation suppresses appetite and improves glycemic control. GIP receptor activation enhances insulin secretion and adipose tissue metabolism. The addition of glucagon receptor agonism promotes hepatic fatty acid oxidation, increases energy expenditure, and may contribute to greater fat mass reduction. This triple mechanism addresses multiple metabolic pathways simultaneously, potentially explaining the enhanced weight loss observed in clinical trials.

Research Highlights

The Phase 2 TRIUMPH trial demonstrated mean weight loss of up to 24.2% at 48 weeks at the 12 mg dose — the highest weight loss reported in any Phase 2 obesity trial at the time. Retatrutide showed significant improvements in glycemic control, blood pressure, and lipid profiles. Subgroup analysis indicated particularly strong responses in male participants. Research has also shown improvements in markers of non-alcoholic fatty liver disease (NAFLD). Phase 3 TRIUMPH trials are ongoing, investigating long-term efficacy and safety.

Dosage & Administration

In clinical trials, retatrutide is administered via subcutaneous injection once weekly, with dose escalation from 1 mg to 12 mg over 16-24 weeks. The titration schedule is designed to minimize gastrointestinal side effects. For research use only (RUO) — not yet FDA-approved.

Safety Profile

Reported side effects are consistent with the incretin class, including nausea, diarrhea, vomiting, and constipation. The glucagon receptor agonism component may contribute to additional effects on hepatic glucose output. Long-term safety data is being collected in ongoing Phase 3 trials. Not yet approved by the FDA for any indication.

References

Jastreboff AM, et al. Retatrutide for obesity (TRIUMPH-1). JAMA. 2023. Eli Lilly clinical trial data (NCT04881760). All content is for educational and research purposes only.

Synergy & Compatibility

(5)

Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.

View full comparison matrix

Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.

Community Observations

(0)

Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.

No approved observations yet. Sign in to contribute.

Research Use Only

For research use only. Not medical advice.

ARIA · Sign in to chat